证券代码：002748 证券简称：世龙实业 公告编号：2025-028 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年6月30日 2、预计的经营业绩：□亏损 □扭亏为盈 R同向上升 □同向下降 二、与会计师事务所沟通情况 本次业绩预告数据是公司财务部门初步测算的结果，未经审计机构审计。 登录新浪财经APP 搜索【信披】查看更多考评等级 报告期内，除烧碱销售价格同比上涨外，公司其他主要产品AC发泡剂、氯化亚砜销售价格较上年同期 略有下降，双氧水产品销售价格同比出现较大幅度地下滑。在此情况下，公司持续加大生产负荷与国内 外市场营销力度，公司及子公司-江西世龙新材料有限公司的主要产品AC发泡剂、氯化亚砜、烧碱、双 氧水及丙酸等产销量均实现同比增长，公司整体营业收入较上年同期有所上升。 与此同时，公司煤、盐、尿素等大宗原材料的采购成本较上年同期均有显著下降，公司产品综合毛利率 同比上升，公司经营业绩亦随之实现大幅增长。 四、风险提示 本次业绩预告数据是公司财务部门初步测算的结果，未经审计机构审计， ...

点击注册小程序 查看完整报告 保健品和OTC产品快速发展，驱动板块收入快速增长 24年健康元（不含丽珠集团、丽珠单抗）保健食品及OTC板块实现营业收入6.97亿元，同比增长约 53.91%。保健食品与OTC板块利用小红书、抖音、微信等新媒体内容渠道，通过达人推荐、健康科普、达 人直播带货等方式创作优质的内容触达用户，传递品牌理念，驱动品牌全渠道的销售增长。我们预计 25~26年板块发展势头良好，收入有望维持较快增速。 研发有序投入，创新转型可期 在创新药领域，公司正逐步推进"机制创新+多适应症覆盖"战略，向"抗感染+呼吸+镇痛"等多元协同方向 发展。其中：1）抗流感新药TG-1000已报产，预计2025年下半年获批上市，该新药具有较长的有效治疗 期；2）在高壁垒复杂制剂方面，沙美特罗替卡松吸入粉雾剂、丙酸氟替卡松雾化吸入用混悬液获得注册 批件，均实现国内首仿。3）在前沿靶点布局方面，TSLP单抗与IL-4R单抗均已进入Ⅱ期临床研究阶段。 在创新药加速向机制升级、适应症精准拓展演进的趋势下，公司在其呼吸系统疾病治疗主线之外，开始布 局多元化创新领域，Nav1.8作为外周神经系统疼痛信号传导的重要钠通道，具有机制 ...

Core Viewpoint - The company is experiencing stable growth in traditional business while new sectors are contributing significantly to high growth, particularly in nuclear medicine, cardiovascular precision intervention, pharmaceutical technology, and biotechnology [1] Group 1: Nuclear Medicine Development - The demand for nuclear medicine is increasing due to aging populations and rising cancer incidence, leading to market expansion for diagnostic and therapeutic applications [1] - The core commercial product, Yttrium-90 microspheres, is expected to grow over 140% in 2024, supported by training of over 1,100 doctors across more than 70 hospitals and inclusion in 45 health insurance plans [1] - The company has 12 innovative RDC products in its pipeline, with 4 approved for clinical research and 3 in Phase III trials, including TLX591-CDx for prostate cancer and TLX250-CDx for renal cell carcinoma [1] Group 2: New Product Opportunities - The company has a diverse range of existing products, but the inclusion of Lishuan in the 10th batch of national procurement is expected to exert short-term pressure on performance [2] - New products in sepsis (STC3141) and ophthalmology are anticipated to have significant market potential, with STC3141 projected to reach peak sales of 10 billion yuan based on a 20% market share and a unit price of 8,000 yuan [3] - The company is also advancing in the ENT field with multiple products in development, including a nasal spray expected to be approved by the end of 2024 [3] Group 3: Financial Projections - Revenue projections for 2025-2027 are estimated at 12.203 billion, 13.292 billion, and 14.663 billion HKD, with net profits of 2.076 billion, 2.422 billion, and 2.764 billion HKD respectively, indicating a low valuation compared to peers [4] - The current price-to-earnings (PE) ratios are projected at 15, 13, and 11 times for the respective years, compared to an average of 25, 23, and 20 times for comparable companies, suggesting the company is undervalued [4]

Group 1 - China State Construction won multiple major projects with a total amount of 21.53 billion yuan, accounting for 1.0% of the audited revenue for 2024 [1] - Zhongtai Chemical's subsidiary has fully launched a methanol upgrading demonstration project, which will further reduce production costs [1] - Wide Special Materials expects a net profit increase of approximately 367.51% year-on-year for the first half of 2025, driven by improved demand and internal optimization [1][2] Group 2 - Longdi Group plans to exercise its preferential subscription rights to participate in the convertible bond issuance of its associate company, Yongqi Electronics, with an investment of no more than 89.249 million yuan [3] - Dayou Energy's subsidiary Mengjin Coal Mine has resumed production after a 38-day suspension due to an accident, with an annual capacity of 1.2 million tons [5] - Shanying International plans to repurchase shares worth between 500 million and 1 billion yuan, with a maximum repurchase price of 2.50 yuan per share [7] Group 3 - Huatai Securities has been approved to issue up to 10 billion yuan in technology innovation bonds to support investment in the technology innovation sector [9] - Weixin Kang's cooperative product, an injectable multivitamin, has passed the consistency evaluation, enhancing its market potential [10] - Jinpu Titanium's controlling shareholder will have 35 million shares auctioned, accounting for 3.55% of the company's total share capital [11] Group 4 - China Pharmaceutical plans to waive its preferential purchase rights for a 24% stake in Chongqing Medical Health Industry Co., with a base transfer price of 2.206 billion yuan [12] - Beijia Clean plans to reduce its shareholding by 1.99% due to funding needs [13] - Anpelon has obtained a design patent for a brake sensor, enhancing its technological capabilities [14] Group 5 - Zhongyue Holdings' subsidiary has received approval for a clinical trial application for a new drug, indicating progress in its pharmaceutical development [14] - Lijun Group's YJH-012 injection has been approved for clinical trials, showcasing its potential in treating gout [16] - Yageer has sold financial assets totaling 4.176 billion yuan, representing 10.13% of its audited net assets for 2024 [15] Group 6 - Tailing Micro expects a net profit increase of approximately 267% year-on-year for the first half of 2025, driven by customer demand and product sales [19] - Baotai plans to invest 287 million yuan to acquire a 51% stake in Shaanxi Wanhao Titanium Technology Co., enhancing its production capabilities [21] - Laime Pharmaceutical has received a drug registration certificate for azithromycin granules, expanding its product portfolio [23] Group 7 - KQ Bio has received approval for a new veterinary vaccine, marking a significant advancement in its product offerings [25] - Robotech signed a contract worth approximately 17.1 million euros, representing over 12.82% of its audited revenue for 2024 [26] - Alloy Investment is planning a control change, leading to a temporary suspension of its stock [27] Group 8 - Huabang Health's subsidiary has received approval for two dermatological drugs, indicating growth in its pharmaceutical pipeline [28] - Lingxiao Pump Industry plans to invest 60 million yuan in wealth management products, optimizing its financial strategy [29] - Jinzhong Technology has won projects totaling 113 million yuan, accounting for 6.39% of its expected revenue for 2024 [31] Group 9 - Yifan Pharmaceutical's subsidiary has received approval for a clinical trial of a growth hormone injection, indicating progress in its research and development [32] - Guiguan Electric plans to invest 395 million yuan in a photovoltaic project, reflecting its commitment to renewable energy [33] - Rili Technology intends to repurchase shares worth between 10 million and 20 million yuan, supporting its stock performance [34] Group 10 - Xingye Securities' chairman has resigned, leading to a change in leadership [35] - Jinko Solar has achieved third-party certification for its high-efficiency solar cells, setting a new industry record [37] - Changan Automobile's controlling shareholder has changed its name, reflecting a rebranding effort [38]

证券代码：301212 证券简称：联盛化学 浙江联盛化学股份有限公司 投资者关系活动记录表 编号：2025-003 | | ☑特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活动 类别 | □媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | ☑现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 方正证券杨宇禄 | | 人员姓名 | 东方财富梅宇鑫 | | | 汇丰晋信王家怡 | | 时间 | 2025 年 6 月 11 日 | | 地点 | 公司会议室 | | 上市公司接待人 | 周正英、杨晓娟 | | 员姓名 | | | | 风险提示： | | | 本次调研涉及公司未来发展展望、预计及目标等均不构成 | | | 本公司的实质承诺，请投资者对此保持足够的风险认识，注意 | | 投资者关系活动 | 投资风险。 | | 主要内容介绍 | 问：请问如何看待今年半年度的业绩情况？如何展望下半年？ | | | 总体而言，今年化工行业较近两年有所回暖，公司第一季 | | | 度的经营情况有所改善，主要产品的市场需求同比也有所增 | | | ...

化工历史发展对工业进步至关重要，促成了各种化学品、材料和产品的商业化生产。然而，目前的化 学生产过程严重依赖化石资源，导致二氧化碳排放激增、资源枯竭等问题。 近年来，以合成生物驱动的生物制造快速发展，赋能各行业转型升级。作为一种新型制造范式，生物 制造不仅为解决资源、能源、环境等全球性挑战提供了新思路，也为人类健康、材料创新等领域带来 了革命性机遇。 生物制造是以微生物细胞或以酶蛋白为催化剂进行化学品合成、或以生物质为原料转化合成能源化学 品与材料，促使能源与化学品脱离石油化学工业路线的新模式。 当前，C1 底物已成为生物制造领 域的首选原料，因其天然丰富、成本效益高以及减少气候变化影响的潜力而备受关注 。 【SynBioCon】 获悉，近日， 北京化工大学谭天伟、中国科学院大连化学物理研究所周雍进、西 安交通大学费强等 人合作综述了 C1 生物制造商业化面临的关键经济和技术障碍 ；此外，还揭示了 提升成本竞争力的可行路线图，强调了其作为传统化学生产的可扩展且可持续的替代方案，在促进碳 中和方面具有的潜力。 图 | 从化学合成到生物制造的转变 1、注重碳转化效率提升 C1 生物制造利用 CO₂、CO、CH₄ ...

Core Viewpoint - The article discusses the increase in patients presenting with "small blisters" on hands and feet during the summer, primarily caused by various skin conditions, with a focus on sweat eczema as the most common cause [1][2]. Group 1: Common Conditions - The most common condition leading to "small blisters" is sweat eczema, characterized by small blisters on the palms and soles, often accompanied by severe itching [2][3]. - Other potential causes include athlete's foot, hand-foot eczema, contact dermatitis, and hand-foot-mouth disease, each with distinct characteristics and treatment approaches [3][4]. Group 2: Symptoms and Diagnosis - Patients typically experience blisters on the sides of fingers, palms, and soles, with symptoms worsening at night or with heat, leading to potential secondary infections if scratched [2][3]. - Sweat eczema is noted for its self-limiting nature, often exacerbating in summer and improving in fall and winter, with recurrent episodes leading to skin thickening and cracking [2][3]. Group 3: Treatment Approaches - Treatment for sweat eczema focuses on symptomatic relief, with options like calamine lotion for itching and topical corticosteroids for severe cases [6]. - Athlete's foot requires maintaining dry skin and may involve antifungal medications, with an emphasis on completing the full treatment course to prevent recurrence [6]. - Hand-foot eczema treatment involves avoiding irritants and may include wet dressings during acute phases, transitioning to topical corticosteroids as the condition stabilizes [6]. - Contact dermatitis treatment emphasizes identifying and removing the irritant, followed by appropriate topical or oral medications as needed [6][7].

编辑丨王多鱼 排版丨水成文 电化学 在合成化学领域正经历复兴，并展现出极具吸引力的优势。通过合成化学策略重新利用天然酶在探索新的化学空间方面具有巨大潜力。包括定向进化、人 工酶和光酶催化在内的精妙策略已展现出其在学术界和工业界拓展酶应用的能力。 然而，电化学与酶的结合主要局限于复制先前已确立的酶的功能。利用电能实现酶的新反应性所面临的关键挑战包括兼容性问题以及异相电子转移的困难 。 如何 利用电化学驱动酶催化，去解锁非天然的新催化模式，仍有待突破。 该研究通过融合电催化和酶催化，成功解锁了 ThDP 依赖酶的新催化功能，实现醛到手性羧酸的动态动力学氧化新转化。该成果开辟了" 电驱动酶催化 "不对称合 成的新范式，为苯丙酸类药物的不对称生物合成提供了新途径。 在这项最新研究中，研究团队报道了通过二茂铁介导的电催化重塑焦磷酸硫胺素 （ThDP） 依赖性酶，从而解锁了α-支链醛的非天然动态动力学氧化。 这种稳健的电酶法能实现布洛芬、萘普生等十种( S )-芳基丙酸类抗炎药物的高效合成， 对映选择性高达 99%ee，适用于过表达该酶的所有细胞，并且酶负载量 低至 0.05 摩尔百分比。 2025 年 5 月 28 日 ...

证券代码：300583 证券简称：赛托生物 回复：尊敬的投资者，您好！公司在原料药产品方面，做了细致布局， 2025 年重点推动推动地塞米松磷酸钠、糠酸氟替卡松、曲安奈德（无菌）、 丙酸氟替卡松（无菌）等原料药新申报工作；完成和诺倍康布地奈德鼻喷 剂、糠酸氟替卡松鼻喷剂、丙酸氟替卡松乳膏 BE 备案工作。另外推动多 款原料药在美国 DMF 和欧盟 CEP 的注册，以获得原料药出口欧美的通行 证，为公司国际化经营战略构筑基石。感谢您对公司的关注！ 5、问：赛托最近几年研发投入是怎么样的？ 山东赛托生物科技股份有限公司 投资者关系活动记录表 编号：DY2025-002 投资者关系活 动类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 其他（山东辖区上市公司 2025 年度投资者网上集体接待日活动） 参与单位名称 及人员姓名 参与公司 2025 年山东辖区上市公司投资者网上集体接待日活动的 投资者 时间 2025 年 5 月 15 日 15:00-16:30 地点 "全景路演"平台（http://rs.p5w.net） 上市公司接待 人员姓名 董事长兼总经理米奇先生 ...

关注纤维素产品的国产替代逻辑演绎 核心观点 行业报告 | 行业研究周报 本周 CS 建筑上涨 2.23%，沪深 300 上涨 2.09%，建筑跑赢大盘 0.14%。中小 市值转型标的涨幅居前，建筑央国企中，四川路桥、中国核建取得较好收 益。近期纤维素相关产品价格显著拉涨，关注国产替代逻辑带来的业绩及 估值催化，重点推荐三维化学。资金层面来看，25 年 1-4 月专项债密集发 行，建议关注后续基建实物工作量的转化节奏。顺周期层面，我们认为 25 年或为煤化工项目落地大年，预计有望获得政策加码支持。新兴业务板块， 建议继续关注与算力、IDC 等相关的投资机会，以及部分中小市值建筑公司 的转型机遇，主题层面建议继续关注西南水电及国际工程相关品种。 建筑装饰 证券研究报告 关注纤维素及其衍生物的国产替代进展 CA（醋酸纤维素）：是用于生产烟草过滤嘴的原材料，全球约 90%以上的醋 酸纤维素用于生产烟用二醋酸纤维素丝束，我国年均消耗 30 万吨，宜宾纸 业持股 67%的四川普什在二醋片及三醋片的生产方面具备领先优势。 CAB（醋酸丁酸纤维素）、CAP（醋酸丙酸纤维素）：物理性质和用途基本 相似，主要用作涂料添加剂。价格 ...